Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 12,900 shares, a growth of 148.1% from the June 15th total of 5,200 shares. Based on an average daily volume of 52,500 shares, the short-interest ratio is currently 0.2 days.

Quoin Pharmaceuticals Trading Up 0.9 %

Shares of QNRX stock traded up $0.01 during trading on Friday, hitting $0.66. The company’s stock had a trading volume of 28,483 shares, compared to its average volume of 313,174. The company has a market cap of $2.61 million, a PE ratio of -0.09 and a beta of 1.97. The business has a fifty day moving average of $0.69 and a 200-day moving average of $1.79. Quoin Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $12.00.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its earnings results on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter. As a group, research analysts predict that Quoin Pharmaceuticals will post -3.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Maxim Group decreased their price objective on Quoin Pharmaceuticals from $15.00 to $4.00 and set a “buy” rating for the company in a report on Friday, March 15th.

Hedge Funds Weigh In On Quoin Pharmaceuticals

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC acquired a new position in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.